Scinai Immunotherapeutics Ltd.
NasdaqCM SCNI
Scinai Immunotherapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2023: USD -25.65
-
Scinai Immunotherapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2022 was USD -42.97, a 19.83% change year over year.
-
Scinai Immunotherapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2021 was USD -53.60, a 75.73% change year over year.
-
Scinai Immunotherapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2020 was USD -220.88, a 26.27% change year over year.
-
Scinai Immunotherapeutics Ltd. Free Cash Flow Per Share for the year ending December 31, 2019 was USD -299.60, a 9.52% change year over year.
| Date | Free Cash Flow Per Share | Return on Assets (ROA) | Return on Equity (ROE) | Return on Capital Employed (ROCE) |
|---|
Don’t Miss A Beat
| CEO | Mr. Amir Reichman M.B.A., M.Sc. |
| IPO Date | May 11, 2015 |
| Location | Israel |
| Headquarters | Jerusalem BioPark Building |
| Employees | 31 |
| Sector | Healthcare |
| Industries | |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email